Research Beyond Borders (RBB) explores emerging science and technologies, for and beyond our core therapeutic areas, to create new opportunities and capabilities for drug discovery and development. RBB helps facilitate Boehringer Ingelheim’s timely and efficient entry into new research fields to develop solutions in areas of high unmet medical need for the benefit of patients.

RBB integrates both internal and external insights and opportunities, and explores new models for collaboration, to bring together the talents and capabilities of our scientists with the strengths of scientists around the world.

Partnering interests include:
• Gene Therapy (AAV focus): Advanced projects applicable to gene therapy; Next generation vectors: tissue or cell specificity; Regulation of transgene expression; Evasion of pre-existing immunity
• Regenerative Medicine: New targets, or methods for identifying targets, implicated in the mobilization and/or differentiation of endogenous stem cells/progenitor cells
• Microbiome: Identification of novel bacteria and bacterial products; and establishing their causal role in human health and disease

For more information please contact:
Dr. Junjun Gao, Boston, USA
junjun.gao@boehringer-ingelheim.com
Dr. Clive Long, Biberach, Germany
clive.long@boehringer-ingelheim.com
Dr. Guido Boehmelt, Vienna, Austria
guido.boehmelt@boehringer-ingelheim.com
Dr. Shinobu Suzuki, Kobe, Japan
shinobu.suzuki@boehringer-ingelheim.com
Dr. Weiyi Zhang, Beijing, China
weiyi.zhang@boehringer-ingelheim.com

If you share our goal of researching and developing new medications to improve the health of people around the world please join us in... Working together for better health